Overview

DPX-Survivac and Checkpoint Inhibitor in DLBCL

Status:
Active, not recruiting

Trial end date:
2022-10-01

Target enrollment:

Participant gender:

Summary

This is a Phase 2 non-randomized, open label, uncontrolled, efficacy and safety study. Study participants will receive two priming doses of 0.5mL of DPX-Survivac 21 days apart and up to six 0.1ml maintenance injections every two months with low dose metronomic oral cyclophosphamide (50 mg BID) for one year or until disease progression, whichever occurs first. Pembrolizumab 200 mg will be administered every 3 weeks for up to one year or until disease progression, whichever occurs first.

Phase:

Phase 2

Details

Lead Sponsor:

Sunnybrook Health Sciences Centre

Collaborators:

ImmunoVaccine Technologies, Inc.
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Merck Sharp & Dohme Corp.

Treatments:

Antineoplastic Agents
Antineoplastic Agents, Alkylating
Cyclophosphamide
Molecular Mechanisms of Pharmacological Action
Pembrolizumab